These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33471819)

  • 21. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
    Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
    Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
    Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
    Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
    PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 27. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
    Grüllich C
    Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
    Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
    Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
    Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
    J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
    Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
    Winters B; Brown L; Coleman I; Nguyen H; Minas TZ; Kollath L; Vasioukhin V; Nelson P; Corey E; Üren A; Morrissey C
    Anticancer Res; 2017 Jul; 37(7):3385-3396. PubMed ID: 28668826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
    Hage C; Rausch V; Giese N; Giese T; Schönsiegel F; Labsch S; Nwaeburu C; Mattern J; Gladkich J; Herr I
    Cell Death Dis; 2013 May; 4(5):e627. PubMed ID: 23661005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Pyridine Bioisostere of Cabozantinib as a Potent
    Karmacharya U; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Wu PK; Park JI
    Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
    Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
    PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.
    Daudigeos-Dubus E; Le Dret L; Bawa O; Opolon P; Vievard A; Villa I; Bosq J; Vassal G; Geoerger B
    Int J Oncol; 2017 Jan; 50(1):203-211. PubMed ID: 27922668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.